Discover
PLRX
Pliant Therapeutics, Inc.
1.02
2 x 0.74
2 x 1.01
bid
ask
+
0.02
2.00%
2 @ 04:00 PM
1.07 +0.05 (5.29%)
| Ytd | -16.39% | |
| 1y | -33.77% |
0.99
day range
1.03
0.99
52 week range
1.87
| Open | 0.99 | Prev Close | 1.00 | Low | 0.99 | High | 1.03 | Mkt Cap | 63.16M |
| Vol | 288.53K | Avg Vol | 477.96K | EPS | -1.53 | P/E | N/A | Forward P/E | -3.32 |
| Beta | 1.09 | Short Ratio | 15.30 | Inst. Own | 111.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.10 | 200-d Avg | 1.19 | 1yr Est | 40.18 |
| Income Statement | |||
| Operating Expenses | 23.86M | ||
| Research and Development Expense | 16.73M | ||
| Selling, General and Administrative Expense | 7.14M | ||
| Operating Income | -23.86M | ||
| Net Income | -22.37M | ||
| Net Income Common Stock | -22.37M | ||
| Net Income Common Stock (USD) | -22.37M | ||
| Consolidated Income | -22.37M | ||
| Earnings per Basic Share | -0.36 | ||
| Earnings per Basic Share (USD) | -0.36 | ||
| Earnings per Diluted Share | -0.36 | ||
| Earning Before Interest & Taxes (EBIT) | -22.37M | ||
| Earning Before Interest & Taxes (USD) | -22.37M | ||
| Weighted Average Shares | 61.92M | ||
| Weighted Average Shares Diluted | 61.92M | ||
| Balance Sheet | |||
| Cash and Equivalents | 26.37M | ||
| Cash and Equivalents (USD) | 26.37M | ||
| Investments | 133.22M | ||
| Investments Current | 133.22M | ||
| Current Assets | 163.14M | ||
| Property, Plant & Equipment Net | 25.61M | ||
| Total Assets | 189.88M | ||
| Debt Current | 2.27M | ||
| Total Debt | 28.74M | ||
| Current Liabilities | 16.48M | ||
| Debt Non-Current | 26.47M | ||
| Total Liabilities | 42.96M | ||
| Accumulated Retained Earnings (Deficit) | -901.81M | ||
| Accumulated Other Comprehensive Income | -397.00K | ||
| Shareholders Equity | 146.93M | ||
| Shareholders Equity (USD) | 146.93M | ||
| Assets Non-Current | 26.74M | ||
| Total Debt (USD) | 28.74M | ||
| Liabilities Non-Current | 26.47M | ||
| Trade and Non-Trade Payables | 1.53M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.09M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 2.69M | ||
| Capital Expenditure | 17.00K | ||
| Net Cash Flow from Investing | 15.49M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 15.47M | ||
| Net Cash Flow from Operations | -12.80M | ||
| Share Based Compensation | 4.19M | ||